Skip to main content

Early Exclusive Enteral Feeding in Preterm Infants: A Meta-Analysis

Journal
Pediatrics (Q1)
Published
13 August 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Inderpreet Santokh, Anurag Fursule, Deepalakshmi Dorasamy, Tejaswi Choudhary, Hazel Carlisle, Chandra Rath
PMID
42586559
DOI
10.1542/peds.2026-076045

Why clinicians should know about it

  • Picked for Neonatology (top studies of the week, 16 August 2026): Enteral feeding meta‑analysis, not respiratory support

Abstract

CONTEXT: Early exclusive enteral feeding (EEF) in preterm infants may provide advantages such as improved nutritional delivery, reduced need for intravenous fluids (IVF), and lower health care costs. However, concerns persist regarding adverse outcomes, particularly necrotizing enterocolitis (NEC). OBJECTIVE: To determine if EEF compared with progressive enteral feed (PEF) is associated with benefits without causing any adverse effects. DATA SOURCES: MEDLINE, EMBASE, EMCARE, CINAHL, Cochrane Library, and clinical trial registries from inception to October 2025. STUDY SELECTION: Randomized controlled trials comparing EEF commenced within 48 hours of birth with PEF in preterm infants. DATA EXTRACTION: Two authors independently extracted data on clinical outcomes of interest using a standardized data collection form. RESULTS: Eleven studies (n = 3145) were included (27+0 to 36+0 weeks). No significant differences were observed in the incidence of NEC stage 2 or greater (pooled relative risk [RR], 1.00; 95% CI, 1.00-1.01; P = .53), hypoglycemia (pooled RR, 1.00; 95% CI, 0.98-1.02; P = .80), or culture-proven sepsis (pooled RR, 1.03; 95% CI, 1.00-1.07; P = .08). EEF was associated with significantly shorter time to full feeds, reduced duration of IVF, faster regain of birth weight, and shorter hospital stay. Certainty of evidence (COE) was moderate for "any NEC" and low to very low for other outcomes. LIMITATIONS: Presence of statistical heterogeneity in some outcomes and lack of blinding in interventions. CONCLUSIONS: EEF appears to be feasible. Based on moderate COE, it does not appear to increase the risk of NEC. Larger and well-designed trials across diverse settings are needed to confirm its safety, evaluate potential benefits-including cost, and assess long-term outcomes.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.